|
The George Institute for Global Health is an independent medical research institute dedicated to improving global health. The George Institute conducts high impact research that targets preventable illnesses and injuries that are the leading causes of death and disability worldwide, including heart and kidney disease, stroke, diabetes, and injury. It is ranked in the top 10 research institutions in the world for research impact by the ''SCImago Institutions Rankings World Reports''.〔(''Scimago Research Rankings'' ) Retrieved on 3 July 2015.〕 The George Institute conducts research in more than 50 countries, with bases in Australia, China, India and the UK. The Institute’s global network conducts research that provides healthcare solutions for hospitals, clinics and medical facilities serving millions of people around the world. With a specific focus on the Asia Pacific regions, The Institute works to identify effective and affordable prevention and treatment strategies, and to strengthen health systems for disease and injury control through: * Large-scale health research that provides the best possible evidence to treat the leading causes of death and disability * Engaging with partners and decision makers to make changes to improve health outcomes, particularly in resource poor areas * Building capacity among health professionals, healthcare providers and education for communities to ensure sustainable health outcomes Since 1999, The George has invested over $250 million across 50 countries. With over 450 staff globally, The Institute collaborates with some of the world’s leading universities, health professionals, hospitals and governments.〔("History of The George Institute" ) Retrieved on 3 July 2015.〕 Areas of expertise include: * Chronic diseases, such as heart disease, kidney disease, diabetes and stroke * Injury prevention, including road safety, falls prevention and frailty management in an effort to avoid disability Founded by Professors Stephen MacMahon and Robyn Norton, The George is affiliated with the universities of Sydney, Peking, and Oxford.〔("Affiliates of The George Institute ) Retrieved on 3 July 2015.〕 The George Institute is currently chaired by Mike Hawker AM and The Institute’s board members are business and scientific leaders in both Australia and internationally. The George employs world-leading scientific experts and has an enviable research track record. The George Institute is one of only three academic research organisations (ARO) accredited to run clinical trials, which ensure unbiased rigor and improved ability to disseminate findings, with the other two AROs being the University of Oxford in the UK and Duke University in the USA. The institute has had major scientific outputs in publications including ''The Lancet'',〔(''The Lancet'' ) ADVANCE study confirms blood pressure lowering benefits of type 2 diabetes patients. Retrieved on 20 April 2012.〕〔(''The Lancet'' ) Early results of major stroke trial, INTERACT, indicates hope for stroke patients. Retrieved 20 April 2012.〕 ''The New England Journal of Medicine'',〔(''The New England Journal of Medicine'' ) ADVANCE study highlights tight blood glucose control benefits for type 2 diabetes patients. Retrieved on 20 April 2012.〕〔(''The New England Journal of Medicine'' ) The SAFE TBI study provides critical information for intensive care units. Retrieved on 20 April 2012.〕 ''PLoS ONE'' Journal,〔(''PLoS ONE'' ) The POLYPILL provides hope for heart care all over the world. Retrieved on 20 April 2012.〕 ''Heart'' (formerly ''British Heart Journal'')〔(''Heart'' ) First study of heart care in Chinese hospitals set to improve care of heart attack patients, CPACS. Retrieved on 20 April 2012.〕 and more.〔("The George Institute Publications" ). Retrieved on 3 July 2015.〕 ==References== 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「George Institute for Global Health」の詳細全文を読む スポンサード リンク
|